EarliPoint Health

Executive Summary

EarliPoint Health is a private diagnostics company based in Rochester, NY, that has developed and achieved FDA clearance for an innovative, non-invasive autism diagnostic device. The device leverages advanced eye-tracking technology to measure how a child visually engages with social stimuli, providing objective and quantifiable data that can support earlier and more accurate autism diagnoses. This approach addresses a critical unmet need in autism care, where the average age of diagnosis remains high, particularly in underserved communities. By enabling detection as early as 16 months, EarliPoint’s solution has the potential to significantly improve developmental outcomes by facilitating timely intervention. The company was founded in 2021 and operates in the growing digital health diagnostics space, aiming to transform autism assessment from subjective observation to evidence-based measurement. Its FDA-cleared status differentiates it in a market with few objective diagnostic tools, positioning it for commercial traction as awareness of early autism detection increases.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch and adoption in U.S. pediatric clinics70% success
• TBDExpansion of FDA clearance to include toddlers under 18 months50% success
• TBDSecuring broad insurance reimbursement coverage40% success